Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study-Reference-Cited by-同舟云学术

Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study

Published:2017 Issue:10 Volume:56 Page:1131-1139
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kinoshita Yoshikazu¹,Hongo Michio²,Kusano Motoyasu³,Furuhata Yoshinori⁴,Miyagishi Hideaki⁴,Ikeuchi Satoshi⁴,

Affiliation:

1. Department of Gastroenterology and Hepatology, Shimane University, School of Medicine, Japan

2. Department of Medicine, Kurokawa Hospital, Japan

3. Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Japan

4. Eisai Co., Ltd., Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/56/10/56_56.7896/_pdf

Reference30 articles.

1. 1. Ariizumi K, Ohara S, Koike T, et al. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by CYP2C19 polymorphism. J Gastroenterol Hepatol 21: 1428-1434, 2006.

2. 2. Kawamura M, Ohara S, Koike T, et al; Study Group of GERD. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 17: 965-973, 2003.

3. 3. Kinoshita Y, Miwa H, Kasugai K. Efficacy of esomeprazole compared with omeprazole in reflux esophagitis patients -A phase III, multicenter, randomized, double-blind, parallel-group trial-. J Jpn Soc Gastroenterol 110: 234-242, 2013.

4. 4. Kinoshita Y, Kazumori H, Ishihara S. Treatment of proton pump inhibitor-resistant patients with gastroesophageal reflux disease. J Gastroenterol 41: 286-287, 2006.

5. 5. Kusano M, Hongo M, Miwa H; J-FAST Group. Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks. Digestion 85: 282-287, 2012.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese consensus on multidisciplinary diagnosis and treatment of gastroesophageal reflux disease 2022;Gastroenterology & Endoscopy;2023-04

2. Drug‐induced peripheral oedema: An aetiology‐based review;British Journal of Clinical Pharmacology;2021-02-20

3. Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis;Journal of Clinical Medicine;2020-08-21

4. Therapeutic Response to 20 mg of Esomeprazole Twice Daily in Patients with Gastroesophageal Reflux Disease-related Non-cardiac Chest Pain: An Open-Label Randomized Pilot Study;The Korean Journal of Gastroenterology;2020-06-25

5. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial;World Journal of Gastroenterology;2019-05-07